A compound genotype encoding KIR2DS4 and its ligand A*11:02 is observed to be associated with reduced EBV/IgA/VCA seroconversion, a risk factor for NPC, but with increased risk of developing NPC (Gao et al. 2017, 2015). Here, CD79A is linked to nasopharyngeal carcinoma.